EP3644968A1 — Levocloperastine fendizoate suspension having enhanced dissolution and resuspendability
Assigned to Ilko Ilac Sanayi ve Ticaret AS · Expires 2020-05-06 · 6y expired
What this patent protects
The present invention relates to an oral pharmaceutical suspension with improved resuspendability and dissolution properties comprising: a therapeutic effective amount of suspended levocloperastine or a pharmaceutically acceptable salt thereof, at least one suspending agent; at l…
USPTO Abstract
The present invention relates to an oral pharmaceutical suspension with improved resuspendability and dissolution properties comprising: a therapeutic effective amount of suspended levocloperastine or a pharmaceutically acceptable salt thereof, at least one suspending agent; at least one surfactant and an effective amount of sweetener composition to provide a palatable taste wherein levocloperastine fendizoate drug substance has particle size distribution (D90) less than 100 µm measured by laser diffraction.
Drugs covered by this patent
- Celebrex (celecoxib) · Pfizer Inc. (originally Searle/Pharmacia)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.